Maintenance of the remission stage of Crohn's disease with adalimumab therapy during pregnancy

Internal Medicine

Volumn 52, Issue 10, 2013, Pages 1049-1053

  Mizoshita, Tsutomu ^a   Tanida, Satoshi ^a   Tsukamoto, Hironobu ^a   Ozeki, Keiji ^a   Katano, Takahito ^a   Ebi, Masahide ^a   Mori, Yoshinori ^a   Kataoka, Hiromi ^a   Kamiya, Takeshi ^a   Joh, Takashi ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Adalimumab; Crohn's disease; Intensive granulocyte and monocyte adsorptive apheresis; Pregnancy

Indexed keywords

ADALIMUMAB; ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; C REACTIVE PROTEIN; CALCIUM; CHLORINE; CHOLESTEROL; CREATININE; GAMMA GLUTAMYLTRANSFERASE; HEMOGLOBIN; POTASSIUM; PREDNISOLONE; SODIUM; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR INHIBITOR;

ABDOMINAL PAIN; ADULT; APHERESIS; ARTICLE; CASE REPORT; COLONOSCOPY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DIARRHEA; ELEMENTAL DIET; ENDOSCOPE; ERYTHROCYTE COUNT; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEMATOCRIT; HUMAN; INFLAMMATION; LEUKOCYTE; PREGNANCY; THROMBOCYTE COUNT; TRANSVERSE COLON; UREA NITROGEN BLOOD LEVEL;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; BLOOD COMPONENT REMOVAL; COLONOSCOPY; COMBINED MODALITY THERAPY; CROHN DISEASE; DRUG HYPERSENSITIVITY; FEMALE; FETUS; HUMANS; MAINTENANCE CHEMOTHERAPY; MESALAMINE; PREDNISOLONE; PREGNANCY; PREGNANCY COMPLICATIONS; REMISSION INDUCTION;

EID: 84877850902     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.52.9466     Document Type: Article

References (27)

1. Takagi S, Utsunomiya K, Kuriyama S, et al. Effectiveness of an 'half elemental diet' as maintenance therapy for Crohn's disease: a randomized-controlled trial. Aliment Pharmacol Ther 24: 1333-1340, 2006.
2. Mizoshita T, Tanida S, Kusumoto S, et al. Adalimumab therapy following granulocyte and monocyte adsorptive apheresis in a patient with Crohn's disease accompanied by chronic myeloid leukemia. Clin J Gastroenterol 5: 302-306, 2012.
3. Van Deventer SJ. Tumour necrosis factor and Crohn's disease. Gut 40: 443-448, 1997.
4. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130: 323-333; quiz 591, 2006.
5. Watanabe M, Hibi T, Lomax KG, et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. J Crohns Colitis 6: 160-173, 2012.
6. Ljung T, Thomsen O, Vatn M, et al. Granulocyte, monocyte/ macrophage apheresis for inflammatory bowel disease: the first 100 patients treated in Scandinavia. Scand J Gastroenterol 42: 221-227, 2007.
7. Suzuki Y, Yoshimura N, Saniabadi AR, Saito Y. Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naive patients with active ulcerative colitis: a prospective uncontrolled study. Dig Dis Sci 49: 565-571, 2004.
8. Mizushima T, Tanida S, Mizoshita T, et al. A complicated case of tacrolimus-induced rapid remission after cesarean section in the early third trimester for refractory severe ulcerative colitis flaring in the initial period of gestation. Case Rep Gastroenterol 5: 144-151, 2011.
9. Tsukada Y, Nakamura M, Nakao M, et al. Therapeutic efficacy of granulocytapheresis in a pregnant woman with severe active ulcerative colits: a case report. J Jpn Soc Dial Therapy 40: 871-875, 2007 (in Japanese, Abstract in English).
10. Mahadevan U, Cucchiara S, Hyams JS, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol 106: 214-223; quiz 224, 2011.
11. Schnitzler F, Fidder H, Ferrante M, et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis 17: 1846-1854, 2011.
12. Vasiliauskas EA, Church JA, Silverman N, Barry M, Targan SR, Dubinsky MC. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 4: 1255-1258, 2006.
13. Vesga L, Terdiman JP, Mahadevan U. Adalimumab use in pregnancy. Gut 54: 890, 2005.
14. Mishkin DS, Van Deinse W, Becker JM, Farraye FA. Successful use of adalimumab (humira) for Crohn's disease in pregnancy. Inflamm Bowel Dis 12: 827-828, 2006.
15. Coburn LA, Wise PE, Schwartz DA. The successful use of adalimumab to treat active Crohn's disease of an ileoanal pouch during pregnancy. Dig Dis Sci 51: 2045-2047, 2006.
16. Van Assche G, Dignass A, Reinisch W, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: special situations. J Crohns Colitis 4: 63-101, 2010.
17. Johnson DL, Jones KL, Chambers CD, Sala E. Pregnancy outcomes in women exposed to adalimumab: The OTIS autoimmune diseases in pregnancy project. Gastroenterology 136 (S-1): A-27, 2009.
18. Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 62: 385-392, 2000.
19. Norgard B, Hundborg HH, Jacobsen BA, Nielsen GL, Fonager K. Disease activity in pregnant women with Crohn's disease and birth outcomes: a regional Danish cohort study. Am J Gastroenterol 102: 1947-1954, 2007.
20. Mogadam M, Dobbins WO 3rd, Korelitz BI, Ahmed SW. Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterology 80: 72-76, 1981.
21. Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med 338: 1128-1137, 1998.
22. Fukuda Y, Matsui T, Suzuki Y, et al. Adsorptive granulocyte and monocyte apheresis for refractory Crohn's disease: an open multicenter prospective study. J Gastroenterol 39: 1158-1164, 2004.
23. Matsui T, Nishimura T, Matake H, Ohta T, Sakurai T, Yao T. Granulocytapheresis for Crohn's disease: a report on seven refractory patients. Am J Gastroenterol 98: 511-512, 2003.
24. Nagase K, Fukunaga K, Kashiwamura S, et al. Immunoregulatory effects of adsorptive granulocyte and monocyte apheresis in patients with drug refractory Crohn's disease. Ther Apher Dial 15: 367-373, 2011.
25. Ozeki K, Tanida S, Mizushima T, et al. Combination therapy with adalimumab plus intensive granulocyte and monocyte adsorptive apheresis induced clinical remission in a Crohn's disease patient with the loss of response to scheduled adalimumab maintenance therapy: a case report. Intern Med 51: 595-599, 2012.
26. Sakuraba A, Motoya S, Watanabe K, et al. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol 104: 2990-2995, 2009.
27. D'Haens GR, Panaccione R, Higgins PD, et al. The london position statement of the world congress of gastroenterology on biological therapy for ibd with the european crohn's and colitis organization: When to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 106: 199-212; quiz 213, 2011.